Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Net Income towards Common Stockholders of -$5.1 million for Q1 2026, up 47.25% year-over-year from -$3.4 million in Q1 2025, and up 8.9% quarter-over-quarter from -$5.6 million in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 47.25% year-over-year to -$5.1 million; the TTM figure through Mar 2026 stood at -$26.4 million (up 41.65% YoY), while the FY2025 annual figure was -$31.0 million, up 34.38% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.1 million, up from -$5.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$5.1 million in Q1 2026, with the low at -$14.0 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$9.9 million (2022), against an average of -$9.8 million.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders plunged 63.63% in 2023, then jumped 53.77% in 2025.
- Galectin Therapeutics' Net Income towards Common Stockholders stood at -$10.7 million in 2022, then grew by 5.97% to -$10.1 million in 2023, then declined by 19.58% to -$12.0 million in 2024, then surged by 53.77% to -$5.6 million in 2025, then advanced by 8.9% to -$5.1 million in 2026.
- Business Quant data shows GALT's Net Income towards Common Stockholders at -$5.1 million in Q1 2026, -$5.6 million in Q4 2025, and -$8.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Galectin Therapeutics | 303.68 Mn | 303.68 Mn | - | -9.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.18 Mn |
| Mar 31, 2026 | -5.07 Mn |
| Dec 31, 2025 | -5.56 Mn |
| Sep 30, 2025 | -8.22 Mn |
| Jun 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -12.03 Mn |
| Sep 30, 2024 | -11.24 Mn |
| Jun 30, 2024 | -12.44 Mn |
| Mar 31, 2024 | -11.50 Mn |
| Dec 31, 2023 | -10.06 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -9.18 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.70 Mn |
| Sep 30, 2022 | -8.58 Mn |
| Jun 30, 2022 | -9.68 Mn |
| Mar 31, 2022 | -9.92 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.56 Mn |